Monika Sopala

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

Jesús F. San Miguel, Vânia Hungria, Sung‐Soo Yoon et al. · The Lancet Oncology · 2014 · 781 citations

Hematological Malignancy, Double-blind Phase 3, Medicine +9

Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial

Simon Bowman, Robert I. Fox, Thomas Dörner et al. · The Lancet · 2021 · 201 citations · Full text

Rheumatoid Disorder, Rheumatology, Autoimmune Disease +12

Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma

Jesús F. San Miguel, Paul G. Richardson, Andreas Günther et al. · Journal of Clinical Oncology · 2013 · 144 citations · Full text

Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial

Jesús F. San Miguel, Vânia Hungria, Sung‐Soo Yoon et al. · The Lancet Haematology · 2016 · 143 citations

Hematological Malignancy, Oncology, Overall Survival +7

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment

Paul G. Richardson, Vânia Hungria, Sung‐Soo Yoon et al. · Blood · 2015 · 130 citations · Full text